source
- Revolution Medicines reports pancreatic cancer drug daraxonrasib extends median survival to 13.2 months in second-line studyRevolution Medicines released detailed data confirming that its experimental pancreatic cancer therapy, daraxonrasib, improved overall survival for patients with advanced disease. In the second‑lin…
- Daraxonrasib shows promising pancreatic cancer results as Chinese lung therapy exceeds expectationsThe latest ASCO updates highlighted detailed data on daraxonrasib, a drug targeting pancreatic cancer, indicating encouraging efficacy signals for patients. In parallel, a lung cancer treatment de…STAT · 5mo agoPositive readoutPositive